Autres langues Akili, Inc.

Actions

AKLI

US00974B1070

Temps réel estimé Cboe BZX Autres places de cotation 15:47:38 01/05/2024			Varia. 5j.	Varia. 1 janv.
0,407 ^USD	+1,75 %		+67,36 %	-17,88 %

30/04	Akili, Inc. réduit ses effectifs	CI
30/04	Akili, Inc. annonce un amendement à son accord de distribution stratégique avec Shionogi & Co, Ltd.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results	30/04
Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product	30/04
Akili, Inc. to Reduce Workforce	30/04
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd	30/04
Akili, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (AKLI) AKILI Posts Q4 Revenue $749,000, vs. Street Est of $0.78M	29/02
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02
PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	28/02
Shionogi & Co., Ltd. - Positive Results from Phase 3 Clinical trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan	27/02
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx for Pediatric ADHD Patients in Japan	27/02
Sector Update: Health Care Stocks Ease Late Afternoon	26/02
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan	26/02
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan	26/02
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan	26/02
Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan	26/02
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates	21/02
Akili Appoints John Spinale to the Board and Audit Committee	21/02
Akili, Inc. Announces Executive Changes, Effective on January 12, 2024	05/01
Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024	05/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Akili, Inc.

Actions

AKLI

US00974B1070

Autres langues

Filtres